Eisai, Biogen Idec deal

The companies provided an update on their March 2014 deal to co-develop and co-promote Eisai’s Alzheimer’s disease candidates E2609 and BAN2401. Biogen disclosed that it paid Eisai $100 million up front under the original terms. In 2Q14, the biotech paid Eisai $35 million after the pharma exercised its option to expand the deal to include Japan. Under the expanded deal, Eisai is eligible for up to $1 billion in development, regulatory and commercialization milestone payments. In markets outside the scope of the deal, Biogen will be eligible for royalties (see BioCentury, March 10, 2014). ...